FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2891824084> ?p ?o ?g. }

• W2891824084 abstract "Hypomethylating agents (HMA), azacitidine, and decitabine are frequently used in the management of myelodysplastic syndromes (MDS). However, there are no clinical trials that have directly compared these agents. We conducted a systematic review and indirectly compared the efficacy of azacitidine to decitabine in MDS.We conducted a comprehensive search of several databases (MEDLINE, EMBASE, Cochrane Central Register of Controlled Trials, and Scopus) through June 28, 2018, without language or time restrictions. Studies were screened by two independent reviewers, and differences were resolved by consensus. The fixed effect model and adjusted indirect comparison methods were used to pool relative risks (RR) of major outcomes of interest (mortality, response rate, quality of life, hematologic improvement, hospitalization, leukemia transformation, transfusion independence).Only four trials met the eligibility criteria. Two trials compared azacitidine to the best supportive care (BSC) and included 549 patients, and the other two compared decitabine to BSC and included 403 patients. The risk of bias was unclear overall. Compared to BSC, azacitidine was significantly associated with lower mortality (RR = 0.83, 95% CI 0.74-0.94, I2 = 89%) whereas decitabine did not significantly reduce mortality (RR = 0.88, 95% CI 0.77-1.00, I2 = 53%). Both drugs were associated with higher partial and complete response compared to BSC. Indirect comparisons were not statistically significant for all the studied outcomes, except for complete response where azacitidine was less likely to induce complete response compared to decitabine (RR = 0.11, 95% CI = 0.01-0.86, very low-certainty evidence).Azacitidine and decitabine are both associated with improved outcomes compared to BSC. The available indirect evidence comparing the two agents warrants very low certainty and cannot reliably confirm the superiority of either agent. Head-to-head trials are needed. In the meantime, the choice of agent should be driven by patient preferences, adverse effects, drug availability, and cost." @default.
• W2891824084 created "2018-09-27" @default.
• W2891824084 creator A5008422091 @default.
• W2891824084 creator A5008757704 @default.
• W2891824084 creator A5035100026 @default.
• W2891824084 creator A5048300954 @default.
• W2891824084 creator A5054802858 @default.
• W2891824084 creator A5059366804 @default.
• W2891824084 creator A5064856519 @default.
• W2891824084 creator A5065058975 @default.
• W2891824084 date "2018-09-19" @default.
• W2891824084 modified "2023-09-25" @default.
• W2891824084 title "A systematic review and network meta-analysis comparing azacitidine and decitabine for the treatment of myelodysplastic syndrome" @default.
• W2891824084 cites W187238933 @default.
• W2891824084 cites W1973018894 @default.
• W2891824084 cites W2000597113 @default.
• W2891824084 cites W2015776863 @default.
• W2891824084 cites W2030437009 @default.
• W2891824084 cites W2037593179 @default.
• W2891824084 cites W2038584260 @default.
• W2891824084 cites W2078294866 @default.
• W2891824084 cites W2081279521 @default.
• W2891824084 cites W2085803274 @default.
• W2891824084 cites W2099326967 @default.
• W2891824084 cites W2106082819 @default.
• W2891824084 cites W2106584820 @default.
• W2891824084 cites W2107398329 @default.
• W2891824084 cites W2114492363 @default.
• W2891824084 cites W2118771330 @default.
• W2891824084 cites W2129975746 @default.
• W2891824084 cites W2131639268 @default.
• W2891824084 cites W2133011229 @default.
• W2891824084 cites W2156098321 @default.
• W2891824084 cites W2169007954 @default.
• W2891824084 cites W2173501537 @default.
• W2891824084 cites W2310716991 @default.
• W2891824084 cites W2326726820 @default.
• W2891824084 cites W2339658711 @default.
• W2891824084 cites W2468996569 @default.
• W2891824084 cites W2605783173 @default.
• W2891824084 doi "https://doi.org/10.1186/s13643-018-0805-7" @default.
• W2891824084 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/6145118" @default.
• W2891824084 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/30227896" @default.
• W2891824084 hasPublicationYear "2018" @default.
• W2891824084 type Work @default.
• W2891824084 sameAs 2891824084 @default.
• W2891824084 citedByCount "13" @default.
• W2891824084 countsByYear W28918240842019 @default.
• W2891824084 countsByYear W28918240842020 @default.
• W2891824084 countsByYear W28918240842021 @default.
• W2891824084 countsByYear W28918240842022 @default.
• W2891824084 crossrefType "journal-article" @default.
• W2891824084 hasAuthorship W2891824084A5008422091 @default.
• W2891824084 hasAuthorship W2891824084A5008757704 @default.
• W2891824084 hasAuthorship W2891824084A5035100026 @default.
• W2891824084 hasAuthorship W2891824084A5048300954 @default.
• W2891824084 hasAuthorship W2891824084A5054802858 @default.
• W2891824084 hasAuthorship W2891824084A5059366804 @default.
• W2891824084 hasAuthorship W2891824084A5064856519 @default.
• W2891824084 hasAuthorship W2891824084A5065058975 @default.
• W2891824084 hasBestOaLocation W28918240841 @default.
• W2891824084 hasConcept C104317684 @default.
• W2891824084 hasConcept C126322002 @default.
• W2891824084 hasConcept C143998085 @default.
• W2891824084 hasConcept C150194340 @default.
• W2891824084 hasConcept C168563851 @default.
• W2891824084 hasConcept C185592680 @default.
• W2891824084 hasConcept C190727270 @default.
• W2891824084 hasConcept C2776239401 @default.
• W2891824084 hasConcept C2780007613 @default.
• W2891824084 hasConcept C2780235182 @default.
• W2891824084 hasConcept C2780240888 @default.
• W2891824084 hasConcept C2780817109 @default.
• W2891824084 hasConcept C44249647 @default.
• W2891824084 hasConcept C55493867 @default.
• W2891824084 hasConcept C71924100 @default.
• W2891824084 hasConcept C82789193 @default.
• W2891824084 hasConcept C95190672 @default.
• W2891824084 hasConceptScore W2891824084C104317684 @default.
• W2891824084 hasConceptScore W2891824084C126322002 @default.
• W2891824084 hasConceptScore W2891824084C143998085 @default.
• W2891824084 hasConceptScore W2891824084C150194340 @default.
• W2891824084 hasConceptScore W2891824084C168563851 @default.
• W2891824084 hasConceptScore W2891824084C185592680 @default.
• W2891824084 hasConceptScore W2891824084C190727270 @default.
• W2891824084 hasConceptScore W2891824084C2776239401 @default.
• W2891824084 hasConceptScore W2891824084C2780007613 @default.
• W2891824084 hasConceptScore W2891824084C2780235182 @default.
• W2891824084 hasConceptScore W2891824084C2780240888 @default.
• W2891824084 hasConceptScore W2891824084C2780817109 @default.
• W2891824084 hasConceptScore W2891824084C44249647 @default.
• W2891824084 hasConceptScore W2891824084C55493867 @default.
• W2891824084 hasConceptScore W2891824084C71924100 @default.
• W2891824084 hasConceptScore W2891824084C82789193 @default.
• W2891824084 hasConceptScore W2891824084C95190672 @default.
• W2891824084 hasIssue "1" @default.
• W2891824084 hasLocation W28918240841 @default.
• W2891824084 hasLocation W28918240842 @default.
• W2891824084 hasLocation W28918240843 @default.
• W2891824084 hasLocation W28918240844 @default.

• next